Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide for weight management in adults with overweight or obesity and type 2 diabetes
2024-519531-41-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Oct 2025
- Modality
- Peptides
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in Overweight, obesity and type 2 diabetes mellitus (T2DM) comparing Cagrilintide with Placebo (2 arms). Primary endpoints: Relative change in body weight and Achievement of ≥ 5% body weight reduction. Planned start Oct 2025; status: authorised.
02
Drugs
cagrilintide
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-519531-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519531-41-00.